DM Clinical Trials

2 recruiting

DM Trials at a Glance

275 actively recruiting trials for dm are listed on ClinicalTrialsFinder across 6 cities in 52 countries. The largest study group is Not Applicable with 85 trials, with the heaviest enrollment activity in Beijing, New York, and Philadelphia. Lead sponsors running dm studies include BrightGene Bio-Medical Technology Co., Ltd., Assistance Publique - Hôpitaux de Paris, and University of Aarhus.

Treatments under study

About DM Clinical Trials

Looking for clinical trials for DM? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new DM trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about DM clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 275 trials

Recruiting
Phase 2

18F-Fluciclovine PET/CT in Multiple Myeloma

Multiple MyelomaNewly Diagnosed Multiple Myeloma (NDMM)Relapsed and/or Refractory Multiple Myeloma (RRMM)
National Cancer Institute (NCI)60 enrolled1 locationNCT06103838
Recruiting
Phase 2

FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)

Dermatomyositis (DM)Juvenile Dermatomyositis (JDM)
National Institute of Environmental Health Sciences (NIEHS)300 enrolled1 locationNCT07111065
Recruiting
Phase 1Phase 2

PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)

Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD
Precision BioSciences, Inc.18 enrolled1 locationNCT07429240
Recruiting
Phase 4

Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes

Type 2 Diabetes Mellitus (T2DM)
University Medical Centre Ljubljana90 enrolled1 locationNCT06613854
Recruiting

Longitudinal Studies of Patient With FPDMM

Rare DiseasesInherited Hematological DiseasesFPDMM
National Human Genome Research Institute (NHGRI)1,000 enrolled1 locationNCT03854318
Recruiting

Optimization and Evaluation of the Diagnosis and Treatment System for Diabetic Retinopathy in Type 2 Diabetes Mellitus

DiabetesType 2 Diabetes Mellitus (T2DM)Diabetic Retinopathy
Yufan Wang2,920 enrolled3 locationsNCT06821399
Recruiting
Phase 2

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

MSI-H/dMMR Solid Tumors
BeiGene200 enrolled29 locationsNCT03736889
Recruiting
Not Applicable

Poi for Mama: a Pilot to Improve Maternal Microbiome and Gestational Diabetes Risk

PregnancyGestational Diabetes Mellitus (GDM)
University of Hawaii50 enrolled3 locationsNCT07446205
Recruiting
Phase 3

Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

MSI-H/dMMR Colorectal CancerResectable Colon Cancer
Akeso386 enrolled1 locationNCT07412613
Recruiting
Not Applicable

ADOLESCENTS IMAGING USING fMRI: Feasibility Study

Diagnosis of BPD Based on the DIB-R Clinical Interview for the BPD GroupDiagnosis of ADHD Using the KSADS-PL for the ADHD GroupAbsence of Pathology on the CBCL and Ab-DIB for the Healthy Control Group+1 more
Etablissement Public de la Sante Mentale de la Somme21 enrolled1 locationNCT07540429
Recruiting
Phase 3

Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1

Myotonic DystrophyDM1Steinert Disease+2 more
Dyne Therapeutics150 enrolled4 locationsNCT07486934
Recruiting
Phase 1

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Amgen464 enrolled6 locationsNCT07403721
Recruiting
Phase 1Phase 2

A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

Type 2 Diabetes Mellitus (T2DM)Obese or Overweight Healthy Volunteers
Alnylam Pharmaceuticals144 enrolled20 locationsNCT06845202
Recruiting
Phase 2

A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM)
Alnylam Pharmaceuticals40 enrolled1 locationNCT07465224
Recruiting
Phase 2

Improving Vaccine Protection for Older Adults

Healthy AdultImmune System Responses and Trained Immunity After AS01 Administration
Singapore General Hospital40 enrolled1 locationNCT07527247
Recruiting
Phase 1

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

Advanced Urothelial CarcinomaOral Drug AdministrationOpen Label
Flare Therapeutics Inc.120 enrolled12 locationsNCT05929235
Recruiting

Invasive Home Ventilation in Denmark

Spinal Cord Injuries (SCI)Neuromuscular Diseases (NMD)MSA - Multiple System Atrophy+5 more
Rigshospitalet, Denmark450 enrolled1 locationNCT07467187
Recruiting
Not Applicable

Determining the Effect of Food Ordering on Blood Glucose In Gestational Diabetes Mellitus (DEFI-GDM)

Gestational Diabetes Mellitus (GDM)
Queen's University, Belfast35 enrolled1 locationNCT06896799
Recruiting
Phase 4

Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination

Diabetes MellitusType 2 DM
Nabiqasim Industries (Pvt) Ltd800 enrolled2 locationsNCT06862739
Recruiting
Not Applicable

Using Virtual Reality to Improve Medical Training

Type 2 Diabetes (T2DM)
Ohio University100 enrolled1 locationNCT07542834